Investment Analysts’ Weekly Ratings Changes for Jazz Pharmaceuticals (JAZZ)

Posted by on Jul 16th, 2026

Jazz Pharmaceuticals (NASDAQ: JAZZ) recently received a number of ratings updates from brokerages and research firms:

  • 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $265.00 to $285.00. They now have an “overweight” rating on the stock.
  • 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $253.00 to $260.00. They now have an “overweight” rating on the stock.
  • 7/9/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $250.00 to $270.00. They now have a “buy” rating on the stock.
  • 7/7/2026 – Jazz Pharmaceuticals had its price target lowered by Truist Financial Corporation from $256.00 to $254.00. They now have a “buy” rating on the stock.
  • 6/29/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
  • 6/12/2026 – Jazz Pharmaceuticals was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
  • 6/10/2026 – Jazz Pharmaceuticals had its price target raised by Bank of America Corporation from $281.00 to $307.00. They now have a “buy” rating on the stock.
  • 6/9/2026 – Jazz Pharmaceuticals had its “market perform” rating reaffirmed by Sanford C. Bernstein.
  • 6/9/2026 – Jazz Pharmaceuticals was given a new $256.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
  • 5/27/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $234.00 to $253.00. They now have an “overweight” rating on the stock.
  • 5/26/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
  • 5/22/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $232.00 to $301.00. They now have an “overweight” rating on the stock.
  • 5/21/2026 – Jazz Pharmaceuticals is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $229.00 price target on the stock.
  • 5/21/2026 – Jazz Pharmaceuticals was upgraded by Sanford C. Bernstein to “hold”.
  • 5/19/2026 – Jazz Pharmaceuticals was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $307.00 price target on the stock, up from $188.00.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president directly owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This represents a 2.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $230.55, for a total value of $266,746.35. Following the transaction, the director owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. This trade represents a 10.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,098 shares of company stock valued at $3,131,906 in the last three months. 4.10% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Featured Articles

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.